Doctor Implores Feds to Consider ‘Miracle’ Ivermectin for COVID Treatment
In an impassioned presentation, Dr. Pierre Kory, a physician at Aurora St. Luke’s Medical Center in Milwaukee implored a U.S. Senate Committee on Homeland Security and Governmental Affairs to consider the steroid Ivermectin in COVID treatment.
“All I ask is for the NIH to review our data that we’ve compiled of all of the emerging data — we have almost 30 studies. Every one is reliably and reproducibly positive showing the dramatic impacts of Ivermectin. Please, I’m just asking that they review our manuscript.”
Dr. Kory called the drug, which has a long history of treating parasites, miraculous.
And when I say miracle, I do not use that term lightly, and I don’t want to be sensationalized when I say that. That is a scientific recommendation based on mountains of data that has emerged in the last three months.
When I am told…that we are touting things that are not FDA- or NIH-recommended, let me be clear. The NIH, their recommendation on Ivermectin, which is to not use it outside of controlled trials, is from August 27th — we are now in December. This is three to four months later.
Mountains of data have emerged from many centers and countries around the world, showing the miraculous effectiveness of Ivermectin. It basically obliterates transmission of this virus. If you take it, you will not get sick.
The paper‘s abstract states:
In March 2020, an expert panel called the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik with the goal of continuously reviewing the rapidly emerging basic science, translational, and clinical data in order to gain insight into and develop a treatment protocol for, COVID-19. At the same time, many centers and groups employed a multitude of novel therapeutic agents empirically and within clinical trials, often during inappropriate time points during this now well-described multi-phase disease. Either as a result of these frequent trial design failures or due to the lack of sufficient anti-viral or anti-inflammatory properties, nearly all trialed agents have proven ineffective in reducing the mortality of COVID-19. Based on a recent series of negative published therapeutic trial results, in particular the SOLIDARITY trial, this virtually eliminates any treatment role for remdesivir, hydroxychloroquine, lopinavir/ritonavir, interferon, convalescent plasma, tocilizumab, and mono-clonal antibody therapy.
This chart shows the death COVID death rate before and after Ivermectin treatment in several Peruvian cities:
